China's first commercial volumetric printing device OrganSEC was launched at Guangzhou Medical University
2024-08-26
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
As one of the important technologies of biomanufacturing, biological 3D printing is widely used in fields such as medicine and life sciences. As one of the most cutting-edge 3D printing technologies in recent years, volumetric printing technology will have a revolutionary impact on existing additive manufacturing methods.
On August 26, the first Green Key Volumetric Printing Technology Application Forum was held at the Panyu Campus of Guangzhou Medical University. This conference is the first domestic seminar with the theme of "Volume Printing Technology Application". It mainly revolves around the application of volumetric printing technology, bringing together bioprinting, bio-ink, life sciences, regenerative medicine, and biomedical engineering to discuss the latest research and application progress in the field of bioprinting.
At the conference, Guangzhou Medical University and relevant units released OrganSEC, the first commercial volumetric printing equipment in China. The equipment was developed by Professor Xie Maobin's team from the School of Biomedical Engineering of Guangzhou Medical University. OrganSEC is the first commercial volumetric printing equipment in China, which uses a back-projection algorithm based on holographic imaging projection technology and CT imaging principles. This technology can project two-dimensional slices of three-dimensional objects into a printing bottle rotating at a certain speed through a specific algorithm, so that the photocurable ink in the printing bottle can form a three-dimensional object in all directions at the same time. Centimeter-sized three-dimensional (active) structures can be printed in only 10-120 seconds, greatly improving printing efficiency and cell survival rate. The cell survival rate after printing is >95%. There is no contact between the printing system and the printed object, and there is no physical damage to the cells.
It is reported that this technology has solved the problems of slow printing speed and low cell survival rate of conventional layer-by-layer printing, and its technical indicators have reached the world's first-class level, filling the domestic gap. OrganSEC will mainly target the organoid market, including organoid preparation, organoid-based personalized tumor medication, and organoid-based drug screening, and will provide accurate personalized medication guidance for cancer patients.
In 2023, Dr. Xie Maobin's team's project "Ultra-fast Volume Printer: A Game Changer in Biological 3D Printing" won the gold medal in the first Guangdong-Hong Kong-Macao Greater Bay Area Doctoral and Postdoctoral Innovation and Entrepreneurship Competition with the highest score. Professor Xie Maobin said: "Previously, the equipment was mainly test equipment (including VBP-T100 and VBP-T200). The equipment released this time has made special improvements to the system hardware and software, especially enriching the printing model library that can be directly called by the equipment."
The forum will also launch the first domestically developed volume printing equipment control software (Haomiao) and release 6 commercial bioprinting inks. Haomiao software integrates control, calculation, parameter adjustment and other functions, and has three special features: rich printing model library, real-time online slicing and multi-file printing, which fills the gap in domestic volume printing control software.
Bio-ink is a material ink developed based on volumetric bio-printing technology, which is suitable for both volumetric printing equipment and other light-curing printing equipment. Professor Xie Maobin's team has developed six commercial bio-printing inks, including visualized GelMA bio-ink, visualized silk fibroin bio-ink, visualized sericin bio-ink, GelMA bio-ink, silk fibroin bio-ink, and sericin bio-ink.
At the meeting, Green Key Biotech will sign a strategic cooperation agreement on the transformation of research results with Newton Optical Research Institute. As a national scientific research market partner, Newton Optical Research Institute will be responsible for the scientific research market promotion and after-sales service support of volume printing equipment and bio-ink. The expected goal is to complete the sales of 200 devices within 3 years, 1,000 devices within 5 years and achieve the goal of first place in the national volume printing market share.
In the expert lecture and seminar session, this conference invited outstanding experts in the field of bioprinting across the country, including Professor He Yong from Zhejiang University, Professor Ruan Changshun from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, Professor Huang Wenhua from Southern Medical University, and Professor Cao Xiaodong from South China University of Technology to hold lectures and special seminars to share the latest research results in bioprinting and volume printing technology.
Text丨Reporter Chen Liang Intern Su LiqiCorrespondent: Guangyi XuanPhoto provided by the correspondent
